A retrospective study of Canadian and British patients with type 2 diabetes found lower rates of cardiovascular death among those taking sodium-glucose cotransporter-2 (SGLT-2) inhibitors than in matched patients who took dipeptidyl peptidase-4 (DPP-4) inhibitors.
The advent of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists could reduce cardiovascular adverse events and progression to end-stage kidney disease, the American Heart Association (AHA) scientific statement noted.
The authors of the retrospective study called for additional research on the pathogenesis of acute kidney injury (AKI) and the associated risk factors, such as medications, in diabetic patients.
A retrospective case-control trial of Italian patients with type 2 diabetes who were given the dipeptidyl peptidase-4 inhibitor upon admission for COVID-19 found significant reductions in mortality and improvements in clinical outcomes.
A three-case series suggests that tighter glycemic control might allow some patients with type 2 diabetes to avoid glucocorticoid treatment for polymyalgia rheumatica.
Once-weekly insulin had similar effects to daily insulin in type 2 diabetes, industry-funded trial finds
HbA1c levels improved by more than a point in insulin-naive patients with inadequately controlled type 2 diabetes who were randomized to a weekly 70-U dose of an investigational insulin.
In an analysis of the Nurses' Health and Health Professionals studies, regular users of proton-pump inhibitors (PPIs) had a 24% higher risk of diabetes than nonusers, with longer duration of use associated with greater risk.
Companies recently recalled metformin hydrochloride for extended-release oral suspension and metformin hydrochloride extended-release tablets USP due to excess amounts of N-nitrosodimethylamine.